Vilon: Research Overview
Vilon (KE; Lys-Glu) is a synthetic dipeptide bioregulator developed by the Khavinson laboratory in Russia. Research in rodent models suggests immunomodulatory and longevity effects; human evidence is sparse and comes from a single research group.
Vilon is a synthetic dipeptide consisting of lysine and glutamic acid (Lys-Glu), designated KE in single-letter code. It was originally identified as an active constituent of Thymalin — the calf thymus polypeptide complex developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Vilon is claimed to have immunomodulatory, oncostatic, and geroprotective properties based on studies from the Khavinson group. As with other Khavinson bioregulators, the research literature is heavily concentrated in one laboratory and predominantly published in Russian or Russian-affiliated journals. No Western regulatory body has approved Vilon for any medical indication.
What Is Vilon?
Vilon (Lys-Glu; molecular weight approximately 275 Da) is the smallest dipeptide bioregulator in the Khavinson series to show biological activity in published research. It was isolated from thymic tissue extracts, and its sequence was determined to account for a portion of Thymalin's immunological effects on lymphocyte proliferation and differentiation. Vilon is fully synthetic and is available as a research compound from multiple vendors, usually in lyophilized form for subcutaneous reconstitution. Khavinson’s group has also studied a structurally related dipeptide, Glu-Trp (EW), which targets similar tissue systems.
Mechanism
Proposed mechanisms for Vilon include epigenetic regulation and direct gene expression modulation. In cultured human lymphocytes, Lys-Glu was reported to significantly increase IL-2 mRNA, a cytokine central to T-cell proliferation. At the chromatin level, Khavinson’s group reported that Vilon and related short peptides can reverse age-related chromatin compaction in human lymphocytes, increasing the proportion of transcriptionally active euchromatin. A 2023 PubMed-indexed study (PMID 37782636) found that the KE peptide regulates SIRT1, PARP1, and PARP2 gene expression in human mesenchymal stem cells during aging, with increased SIRT1 expression in young cells and modulation of PARP-family proteins that influence DNA repair and aging pathways. The mechanistic claims — particularly direct peptide-DNA interaction — are not established mainstream molecular biology and require independent validation.
What the Research Shows
The most frequently cited study is Khavinson and Anisimov (2000, PMID 10944717), which reported that subcutaneous administration of Vilon to female CBA mice starting at 6 months of age increased physical activity, prolonged mean lifespan, and significantly inhibited the development of spontaneous tumors compared to controls. This study is published in Dokl Biol Sci (translated from the Russian Doklady Akademii Nauk). It is a rodent study from the developing group and has not been independently replicated.
A 2001 PubMed-indexed study (PMID 11586413) examined the effect of Vilon on digestive enzyme activity in rats of various ages, noting age-dependent changes in enzymatic response. The 2023 human mesenchymal stem cell study (PMID 37782636) represents more recent molecular work from the same group. There are no published independent human clinical trials evaluating Vilon’s longevity or immunological claims. The evidence base is entirely preclinical or comes from Khavinson-affiliated researchers.
Reported Dose Ranges
Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.
Published dose-finding studies are limited; values reported here come from Khavinson laboratory animal and clinical literature and have not been validated in modern clinical trials. Russian clinical references describe subcutaneous administration in the range of 0.1–1 mg per injection, typically in short courses. Animal studies have used weight-based dosing not directly translatable to humans. No English-language pharmacokinetic studies for Vilon as a standalone compound have been published as of 2026.
References
1. Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261-263. PMID 10944717.
2. Khavinson V et al. Effect of the dipeptide vilon on activity of digestive enzymes in rats of various ages. Bull Exp Biol Med. 2001;132(3):862-864. PMID 11586413.
3. Khavinson V et al. KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging. Biochem Biophys Res Commun. 2023. PMID 37782636.
- What is the relationship between Vilon and Thymalin?
- Thymalin is a natural polypeptide complex extracted from calf thymus containing multiple peptide fractions. Vilon (Lys-Glu) was identified by Khavinson's group as one of the active dipeptide sequences within Thymalin's composition that contributes to its immunological effects. Vilon is now synthesized independently and is a distinct, simpler compound.
- Is there any independent evidence for Vilon’s anti-aging effects?
- As of 2026, no independent research group outside the Khavinson laboratory has published replication studies on Vilon’s longevity or anti-tumor effects in animals, and no controlled human clinical trials have been published. The claims are based on rodent studies from one laboratory. This should be clearly understood when evaluating the compound.
- How does Vilon differ from other Khavinson dipeptides like Epithalon?
- Epithalon (Ala-Glu-Asp-Gly, AEDG) is a tetrapeptide — four amino acids — derived from the pineal gland, with research focused primarily on telomerase activation and circadian rhythm modulation. Vilon (Lys-Glu) is a dipeptide — two amino acids — derived from the thymus, with research focused on immune regulation and longevity outcomes. They are structurally distinct with different proposed mechanisms and different target tissues.
- Khavinson & Anisimov 2000 — Vilon inhibits spontaneous tumors and increases lifespan in mice (PMID 10944717). https://pubmed.ncbi.nlm.nih.gov/10944717/
- Khavinson et al. 2001 — Effect of Vilon on digestive enzyme activity in rats (PMID 11586413). https://pubmed.ncbi.nlm.nih.gov/11586413/
- Khavinson et al. 2023 — KE peptide regulates SIRT1/PARP1/PARP2 in mesenchymal stem cells (PMID 37782636). https://pubmed.ncbi.nlm.nih.gov/37782636/